@LaraPo I wonder if a mesotherapy approach might be useful with this drug for skin aging? (for easier self-administration and also to avoid any possible systemic issues that might arise with simultaneous use with rapamycin):
The Novartis patent suggests:
Preferred forms for administration include forms suitable for parenteral administration , e . g . by injection or infusion , for example by bolus injection or continuous infusion .
Where the product is for injection or infusion , it may take the form of a suspension , solution or emulsion in an oily or aqueous vehicle and it may contain formulatory agents , such as as suspending , preservative , stabilising and / or dispersing agent . Alternatively , the antibody molecule may be in dry form , for reconstitution before use with an appropriate sterile liquid .
Once formulated , the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals . However , it is preferred that the compositions are adapted for administration to human subiects .
The pharmaceutical compositions of this invention may be administered by any number of routes including , but not limited to , oral , intravenous , intramuscular , intra - arterial , intramedullary , intrathecal , intraventricular , transdermal , transcutaneous ( for example , see WO 98 / 20734 ) , subcutaneous , intraperitoneal , intranasal , enteral , topical , sublingual , intravaginal or rectal routes .
Hyposprays may also be used to administer the pharmaceutical compositions of the invention . Typically , the therapeutic compositions may be prepared as injectables , either as liquid solutions or suspensions . Solid forms suitable for solution in , or suspension in , liquid vehicles prior to injection may also be prepared .
Direct delivery of the compositions will generally be accomplished by injection , subcutaneously , intraperitoneally , intravenously or intramuscularly , or delivered to the interstitial space of a tissue . The compositions can also be administered into a lesion . Dosage treatment may be a single dose schedule or a multiple dose schedule.
Source: Novartis Patent https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&locale=en_EP&CC=NL&NR=300749I2&KC=I2
and this is also interesting:
Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion
https://onlinelibrary.wiley.com/doi/10.1111/exd.12863
More information about intra-dermal injections (mesotherapy):
https://opentextbc.ca/clinicalskills/chapter/6-7-intradermal-subcutaneous-and-intramuscular-injections/
